XML 50 R39.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaboration and Licensing Agreements (Details)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jul. 31, 2016
USD ($)
Jun. 30, 2016
USD ($)
product
item
Sep. 30, 2015
USD ($)
item
Jan. 31, 2013
USD ($)
item
Feb. 28, 2009
item
Sep. 30, 2018
USD ($)
Dec. 31, 2017
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2018
USD ($)
item
Sep. 30, 2017
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2013
USD ($)
Option and license agreement | Alexion Pharmaceuticals, Inc.                          
Collaboration research and licensing agreements                          
Nonrefundable upfront payment       $ 3,000,000                  
Revenue recognized           $ 9,000,000   $ 0 $ 9,000,000 $ 0      
Number of different target programs | item       6                  
Research license term       5 years                  
Annual maintenance fees       $ 2,000,000                  
Milestone payment received                 17,500,000        
Deferred revenue           0     0        
2009 Research License and Commercialization Agreement | CSL Limited                          
Collaboration research and licensing agreements                          
Revenue recognized           0   0 0 3,500,000     $ 3,500,000
Deferred revenue           0     0        
Number of commercial licenses | item         1                
Collaboration And License Agreement | Novartis                          
Collaboration research and licensing agreements                          
Nonrefundable upfront payment $ 150,000,000                        
Revenue recognized           20,040,000   0 20,040,000 0      
Deferred revenue           40,100,000     40,100,000        
Milestones or royalties in transaction price                 0        
Collaboration And License Agreement | Novartis | Maximum                          
Collaboration research and licensing agreements                          
Potential milestone payment           2,400,000,000     $ 2,400,000,000        
Collaboration And License Agreement | Novartis | Bispecific FC Technologies                          
Collaboration research and licensing agreements                          
Number of development stage products | product   2                      
Collaboration And License Agreement | Novartis | Bispecific FC Technologies | XmAb14045                          
Collaboration research and licensing agreements                          
Allocation of consideration to deliverables   $ 27,100,000                      
Collaboration And License Agreement | Novartis | Bispecific FC Technologies | XmAb13676                          
Collaboration research and licensing agreements                          
Allocation of consideration to deliverables   31,400,000                      
Collaboration And License Agreement | Novartis | Global Discovery Program                          
Collaboration research and licensing agreements                          
Number of bispecific drug candidates | item                 4        
Allocation of consideration to deliverables   $ 20,050,000                      
Number of discovery programs | item   4                      
Right to substitute identified target period                 5 years        
Collaboration And License Agreement | Novartis | Global Discovery Program | ASU 2014-09                          
Collaboration research and licensing agreements                          
Revenue recognized           20,040,000         $ 20,050,000    
Collaboration And License Agreement | Novartis | Global Discovery Program | Maximum                          
Collaboration research and licensing agreements                          
Number of antibody targets for which bispecific technology applied | item   4                      
Collaboration And License Agreement | Novartis | FC Licenses                          
Collaboration research and licensing agreements                          
Allocation of consideration to deliverables   $ 11,300,000                      
Collaboration And License Agreement | Novartis | FC Licenses | Maximum                          
Collaboration research and licensing agreements                          
Number of targets against which non-exclusive license is provided | item   10                      
Research and License Agreement 2015 | Amgen, Inc.                          
Collaboration research and licensing agreements                          
Nonrefundable upfront payment     $ 45,000,000                    
Potential milestone payment     $ 1,700,000,000                    
Revenue recognized           0 $ 10,000,000 $ 0 $ 0 $ 0      
Number of different target programs | item     6                    
Allocation of consideration to deliverables           55,000,000     55,000,000        
Deferred revenue           0     0        
Milestones or royalties in transaction price             $ 0            
Research and License Agreement 2015 | Amgen, Inc. | ASU 2014-09                          
Collaboration research and licensing agreements                          
Revenue recognized                       $ 31,250,000  
Research and License Agreement 2015 | Amgen, Inc. | CD38 Program                          
Collaboration research and licensing agreements                          
Allocation of consideration to deliverables           23,750,000     $ 23,750,000        
Research and License Agreement 2015 | Amgen, Inc. | Discovery Program                          
Collaboration research and licensing agreements                          
Research license term                 3 years        
Allocation of consideration to deliverables           $ 6,250,000     $ 6,250,000        
Number of discovery programs | item                 5        
Additional research term                 1 year        
Previous targets which bispecific technology will be applied | item     5